15th International Drug Resistance Workshop, 13-17 June 2006, Sitges, Spain
The annual resistance meeting is a closed workshop for around 200 delegates, nearly all of whom are presenting authors for research papers that are discussed at the meeting.
Although much of the meeting is focused on basic science, there are always studies with important implications for current clinical practice.
The following reports are included in this years review of the meeting.
- Resistance implications of monotherapy with lopinavir/r (Kaletra)
- Ritonavir reduces virological failure and resistance in treatment naive patients treated with atazanavir
- Resistance to darunavir (TMC-114): predicting responses for treatment experienced patients
- Epidemiological studies and transmission of resistance: evidence for optimism or issues with interpretation?
- K103N containing variants persist longer in women with subtype D and with higher viral loads
- No subtype-based differences in baseline levels of K103N-containing variants in women receiving single dose nevirapine
- Phenotypic NNRTI resistance and genetic diversity in antiretroviral naive women
- High prevalence of the K65R mutation in Botswana patients treated with ddI/d4T-based regimens
- Potential for easier selection of K65R mutation with tenofovir pressure in subtype C HIV-1 isolates
- Categorisation of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method may be useful in resource limited settings
- Limitations in online tools to identify HIV-1 subtypes
- Resistance implications from PrEP and microbicide studies in macaques
- Low-level resistance linked to treatment failure: a role for more sensitive testing for naive patients
- Testing for resistance after starting treatment
Abstracts are available online at the excellent conference database published by aegis.org where individual abstract pdf files can also be downloaded.